ChemoCentryx : Corporate September 2020 Presentation

New Ideas. Better Medicines.

Presentation to Investors September 2020

Forward‐Looking Statements

This presentation contains forward‐looking statements that involve substantial risks and uncertainties. In some cases, you can identify forward‐looking statements by the following words: "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "contemplate," "believe," "estimate," "predict," "project," "seek," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward‐looking statements contain these words. These statements relate to future events or our future financial performance or condition and involve known and unknown risks, uncertainties and other factors that could cause our actual results, levels of activity, performance or achievement to differ materially from those expressed or implied by these forward‐looking statements. These risks, uncertainties and other factors are described more fully in our periodic reports filed with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10‐K for the year ended December 31, 2019, filed with the SEC on March 10, 2020, and our Form 10‐Q filed on August 10, 2020, particularly in the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations". In light of the significant uncertainties in our forward‐looking statements, you should not place undue reliance on these statements or regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified timeframe, or at all. The forward‐looking statements contained in this presentation represent our estimates and assumptions only as of the date of this presentation and, except as required by law, we undertake no obligation to update or revise publicly any forward‐looking statements, whether as a result of new information, future events or otherwise after the date of this presentation.

This presentation also contains estimates, projections and other information concerning our industry, our business, and the markets for our drug candidates, as well as data regarding market research, estimates and forecasts prepared by our management. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information.

2

ChemoCentryx:

Inhibiting Disease‐Driving Chemoattraction

• Chemoattractant receptors (chemokine receptors and complement receptors) attract and activate destructive inflammatory cells in disease
• CCXI platform: targeted therapeutics with highly specific orally‐administered small molecule inhibitors of chemoattractant receptors
• CCXI Doctrine: Precise mechanism -precise
  medicine
  • Anti‐inflammatory, not immunosuppressive
• Beyond chemokine receptors: we have also leveraged our medicinal chemistry expertise to develop unique orally administered small molecule checkpoint inhibitors for oncology

Extracellular

Cell

membrane

Chemoattractant

(e.g. C5a, chemokine MCP‐1)

Receptor

(e.g. C5a Receptor, CCR2)

Intracellular

3

CCXI Broad Pipeline from Novel Discovery Platform

•

	DRUG/				NDA
THERAPEUTIC AREA	TARGET	INDICATION	PRECLINICAL PHASE 1	PHASE 2 PHASE 3 Submitted
Complement Inhibition	Avacopan		ANCA‐ASSOCIATED VASCULITIS
in Orphan Diseases	(formerly CCX168)/		C3 GLOMERULOPATHY
C5aR
			HIDRADENITIS SUPPURATIVA

CCX559/ PD‐1 /

PD‐L1

ORALLY ADMINISTERED CHECKPONT INHIBITORS

Immuno‐Oncology

IBD and Other

Inflammatory and

Autoimmune Diseases

CCX507/

CCR9	IBD: ULCERATIVE COLITIS
CCX587/
TH17 DRIVEN DISEASE
CCR6

4